Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Although major improvements in the management and treatment of diabetic foot ulcers have been made, the clinical and financial burden of such long-term wounds is still high and is likely to increase as the general population ages. The large population affected by diabetic foot ulcers and the high rates of failure ending with amputation even with the best therapeutic regimens have resulted in the development of new therapies. I-020201 is a bioactive therapy intended for topical treatment of hard-to-heal diabetic foot ulcers, stimulating the granulation tissue formation. This study aims to evaluate the safety and efficacy of I-020201 in adjunct to good standard of care in patients with chronic diabetic foot ulcer.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Good Standard of Care (GSoC) | Experimental | Twice per week |
|
| GSoC + vehicle | Experimental | Twice per week |
|
| GSoC + I-020201 (33microg) | Experimental | Twice per week |
|
| GSoC + I-020201 (100microg) | Experimental | Twice per week |
|
| GSoC + I-020201 (300microg) | Experimental | Twice per week |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Good Standard of Care (GSoC) | Procedure | Procedural treatment twice per week |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage reduction in ulcer surface area | 4 weeks after treatment start |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of complete wound closure (full re-epithelialization with confirmation 4 weeks afterwards) | At 12 and 16 weeks after treatment start | |
| Incidence of complete wound closure (full re-epithelialization with confirmation 4 weeks afterwards) | Within the whole study period (28 weeks after treatment start) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
pregnant or breast-feeding
known or suspected allergies to any of the components of the I-020201
uncontrolled anemia (Hb < 9 g/dL in females and < 10 g/dL in males)
hypoalbuminemia (albumin < 3 g/dL)
overtly infected target ulcer (as judged by investigator)
highly exuding wounds (wounds that require a daily dressing change)
osteomyelitis
systemic infections
acute Charcot foot and severe chronic Charcot deformity
ABPI < 0.7 or ankle systolic pressure < 70 mm Hg
one of the following findings (only 1 out of 3 tests is required):
suspicion, presence or history of systemic or local cancer or tumor of any kind
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Virginia Jamieson, MD | Kuros Biosurgery | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Diabetologické centrum, I. Interní klinika FN Hradec Králové, Fakultní nemocnice Hradec Králové (21) | Hradec Králové | 500 05 | Czechia | |||
Not provided
Not provided
Not provided
Not provided
Not provided
| Vehicle | Biological | Topical fibrin as an adjunct to GSoC twice per week |
|
| I-020201 | Biological | Topical treatment with 3 different concentrations as an adjunct to GSoC twice per week |
|
| Time to complete wound closure (full re-epithelialization with confirmation 4 weeks afterwards). | At any time during the study |
| Incidence of treatment failure defined as <30% decrease in ulcer size | After 8 weeks of treatment |
| Incidence of patients with ulcer recurrence | Up to 16 and 28 weeks after treatment start |
| Incidence of treatment-related adverse events (systemic and at the target ulcer) and all AEs/SAEs | During the whole study period |
| Changes in systemic PDGF-AB and antibody levels against TG-PDGF.AB and aprotinin | At 1, 4, 12, 16 and 20 weeks after treatment start |
| Changes in vital signs, body weight, physical examination and laboratory parameters | Throughout the study and 28 weeks after treatment start |
| Interní klinika 2. Lékařské fakulty UK a FN Motol, Fakultní nemocnice Motol (22) |
| Prague |
| 150 06 |
| Czechia |
| Oddelení diabetologie - Podiatricka ambulance Krajská zdravotní a.s.- Masarykova nemocnice v Ústí nad Labem o.z. (23) | Ústí nad Labem | 401 13 | Czechia |
| Lékařský dum Ormiga Angiologická a diabetologická ambulance (20) | Zlín | 760 01 | Czechia |
| Klinikum Sindelfingen-Böblingen (01) | Böblingen | 71031 | Germany |
| SRH Klinikum Karlsbad-Langensteinbach (04) | Karlsbad | 76307 | Germany |
| Klinikum Stuttgart Bürgerhospital (03) | Stuttgart | 70191 | Germany |
| Universitätsklinik Tübingen Chirugische Poliklinik (02) | Tübingen | 72076 | Germany |
| Budai Irgalmasrendi Közhasznú Non-Profit Kft (35) | Budapest | 1027 | Hungary |
| Fõvárosi Önkormányzat Egyesített Szent István és Szent László Kórház - Rendelõintézet Sebészeti Osztály (32) | Budapest | 1097 | Hungary |
| Fővárosi Önkormányzat Szent Imre Kórház Operativ Szakmák Mátrix Szervezete Általános Sebészeti Profil (33) | Budapest | 1115 | Hungary |
| Esztergom Város Önkormányzat Vaszary Kolos Kórház Sebészeti Osztály (34) | Esztergom | 2500 | Hungary |
| Kaposi Mór Oktató Kórház (38) | Kaposvár | 7400 | Hungary |
| Bács-Kiskun Megyei Önkormányzat Kórháza Szegedi Tudományegyetem Általános Orvostudományi Kar Oktató Kórháza, 2. Belgyógyászat (31) | Kecskemét | 6000 | Hungary |
| Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház Érsebészeti Osztály (30) | Miskolc | 3526 | Hungary |
| PTE Klinikai Központ Érsebészeti Klinikai Tanszék (36) | Pécs | 7623 | Hungary |
| SZTE Szent-Györgyi Albert Klinikai Centrum (37) | Szeged | 6720 | Hungary |
| Institutul Naţional de Diabet, Nutriţie şi Boli Metabolice "Prof. Dr. N. C. Paulescu" (42) | Bucharest | 020475 | Romania |
| Spitalul Clinic Judeţean de Urgenţă Cluj (43) | Cluj-Napoca | 400006 | Romania |
| Spitalul Clinic Judeţean Mureş, Clinica de Dermatologie (40) | Tg Mures | 540342 | Romania |
| Cabinet Medical Individual DermaMed (41) | Tg. Mures, | 540530 | Romania |
| Spitalul Clinic Judetean de Urgenta Timisoara (45) | Timișoara | 300723 | Romania |
| Moscow City Clinical Hospital # 13 (11) | Moscow | 115280 | Russia |
| Moscow State University of Public Health "City Clinical (17) | Moscow | 115432 | Russia |
| Department of Endocrinology and Diabetes, Russian State Medical University, Moscow City Clinical Hospital # 1 (15) | Moscow | 117049 | Russia |
| Department of Diabetic Foot Endocrinology dispensary (12) | Moscow | 119034 | Russia |
| Endocrinology Clinic of the State Educational Institute of High Professional Education (18) | Moscow | 119992 | Russia |
| Federal State Institution "Federal Bureau of Medical Social Expertise" (10) | Moscow | 123448 | Russia |
| Moscow Clinical Hospital # 81 (14) | Moscow | 127644 | Russia |
| Klinički centar Srbije, Institut za endokrinologiju, dijabetes i bolesti metabolizma (51) | Belgrade | 11 000 | Serbia |
| Clinical Centre Kragujevac (54) | Kragujevac | 34 000 | Serbia |
| Clinical Centre Nis (50) | Niš | 18000 | Serbia |
| Clinical Centre of Vojvodina (53) | Novi Sad | 21 000 | Serbia |
| Health Centre Valjevo (52) | Valjevo | 14 000 | Serbia |
| ID | Term |
|---|---|
| D017719 | Diabetic Foot |
| D014456 | Ulcer |
| ID | Term |
|---|---|
| D003925 | Diabetic Angiopathies |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D016523 | Foot Ulcer |
| D007871 | Leg Ulcer |
| D012883 | Skin Ulcer |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D048909 | Diabetes Complications |
| D003920 | Diabetes Mellitus |
| D004700 | Endocrine System Diseases |
| D003929 | Diabetic Neuropathies |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided